Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Muhammad Aasim Ali: Treatment Strategies for Chemotherapy-Induced Cytopenias
Muhammad Aasim Ali/LinkedIn
May 9, 2026, 22:12

Muhammad Aasim Ali: Treatment Strategies for Chemotherapy-Induced Cytopenias

Muhammad Aasim Ali, Pharmacist at Premium Care Medical Polyclinic, shared a post on LinkedIn:

”Cancer Myelosuppression Treatment

Cancer therapy–induced myelosuppression:

Neutropenia:

Granulocyte colony-stimulating factors include:

  • filgrastim
  • pegfilgrastim

They act on myeloid progenitors via the G-CSF receptor to accelerate neutrophil proliferation, differentiation, and release from the bone marrow.

Pegylation prolongs half-life and allows once-per-cycle dosing.

These agents reduce febrile neutropenia risk but can cause bone pain and, rarely, splenic complications.

Anemia:

Chemotherapy-induced anemia is addressed with erythropoiesis-stimulating agents such as:

  • epoetin alfa
  • darbepoetin alfa

These drugs activate erythropoietin receptors on erythroid progenitors to increase erythrocyte production.

However, their use is restricted due to risks of thromboembolism and potential tumor progression, and they are generally reserved for palliative settings with careful hemoglobin targets.

Thrombocytopenia:

  • Oprelvekin: a recombinant human IL-11 drug used to prevent severe thrombocytopenia and reduce the need for platelet transfusions.

It acts as a thrombopoietic growth factor that stimulates the bone marrow to produce more megakaryocytes and platelets.”

Muhammad Aasim Ali: Treatment Strategies for Chemotherapy-Induced Cytopenias

Stay updated with Hemostasis Today.

Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine Muhammad Aasim Ali thrombosis
NewsFeed